Search

Your search keyword '"Priyanka M Reddy"' showing total 3 results
Start Over Author "Priyanka M Reddy" Publication Year Range Last 50 years
3 results on '"Priyanka M Reddy"'

1. Impact of Age on Cognitive Testing Practice Effects and Cardiorespiratory Responses

Author

Priyanka M. Reddy BS, Kulsum Abdali MS, Sarah E. Ross DO, Sandra Davis MD, Robert T. Mallet PhD, and Xiangrong Shi PhD

Subjects
Geriatrics, RC952-954.6
Abstract

Objective: This study tested the hypothesis that healthy aging attenuates cognitive practice effects and, consequently, limits the familiarity-associated reductions in heart rate (HR) and breathing frequency (BF) responses during retesting. Methods : Twenty-one cognitively normal older and younger adults (65 ± 2 vs. 26 ± 1 years old) participated in the study. Mini-Mental State Examination (MMSE), Digit-Span-Test (DST), Trail Making Test (TMT-B), and California Verbal Learning Test (CVLT-II) were administered twice at 3-week intervals, while HR and BF were monitored by electrocardiography and plethysmography, respectively. Results : Cognitive performances were not affected by the age factor, and the retest factor only affected CVLT-II. HR and BF increased only in the younger adults ( p

Published
2024
Full Text
View/download PDF

3. Investigative Landscape in Advanced Non-Melanoma Skin Cancers

Author

Monaliben Patel, Min Yao, and Priyanka M Reddy

Subjects
0301 basic medicine, Oncology, medicine.medical_specialty, Skin Neoplasms, Vismodegib, Pembrolizumab, Sonidegib, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, Internal medicine, medicine, Humans, Pharmacology (medical), Molecular Targeted Therapy, Hedgehog, Immune Checkpoint Inhibitors, Clinical Trials as Topic, business.industry, Squamous cell skin cancer, Hedgehog signaling pathway, Basal cell epithelioma, Clinical trial, 030104 developmental biology, chemistry, Carcinoma, Basal Cell, 030220 oncology & carcinogenesis, Carcinoma, Squamous Cell, business, medicine.drug
Abstract

Advanced non-melanoma skin cancers have been challenging to treat due to limited treatment options. Treatment paradigm has shifted with the approval of immunotherapeutic agents cemiplimab and pembrolizumab which have been a key development and have changed the landscape of advanced or metastatic squamous cell skin cancers. Hedgehog inhibitors, vismodegib and sonidegib, remain upfront options for advanced or metastatic basal cell carcinomas. Current clinical trials are continuing to evaluate the use of immune checkpoint inhibitors and hedgehog pathway inhibitors. There is further need for ongoing research and development of new therapies in both malignancies.

Published
2021

Catalog

Books, media, physical & digital resources
See catalog results